HMGXB4

HMGXB4 (HMG2L1) is a nuclear HMG-box transcriptional activator that modulates cell differentiation, inflammation, and transposon regulation. It negatively regulates Wnt/β-catenin signaling through interaction with NLK (PMID:12875653) and represses smooth muscle differentiation by binding myocardin via their N-terminal domains, thereby disrupting the SRF–myocardin complex on smooth muscle gene promoters (PMID:20511232). HMGXB4 drives proinflammatory gene expression by directly binding the Nos2 and Icam1 promoters in macrophages and endothelial cells, and genetic deletion in mice protects against LPS-induced lung injury and sepsis lethality (PMID:33563757). It also serves as a host factor for Sleeping Beauty transposon transactivation, itself regulated by ERK2/ELK1-mediated transcriptional induction, KRAB-ZNF/TRIM28 repression, and SUMOylation-dependent nucleolar compartmentalization that modulates its transcriptional activator function (PMID:18071335, PMID:37108449).

1. 2003 Medium

   The first molecular function assigned to HMGXB4 established it as a negative regulator of Wnt/β-catenin signaling, answering how NLK-associated factors restrain this pathway.

   Evidence Yeast two-hybrid identification of NLK interaction, Xenopus embryo injection blocking Wnt-induced axis duplication, mammalian reporter assays

   PMID:12875653

   Open questions at the time

   • No direct biochemical mechanism for how HMGXB4–NLK interaction suppresses β-catenin transcriptional activity
   • Interaction validated by Y2H without reciprocal co-IP in mammalian cells
   • Physiological relevance in mammalian Wnt signaling contexts not tested
2. 2007 Medium

   HMGXB4 was identified as a host-encoded transcriptional activator of the Sleeping Beauty transposon 5′-UTR, revealing a transposon–host regulatory interface where transposase antagonizes HMGXB4-driven expression.

   Evidence Reporter assays and transposon activity assays in human cells with HMGXB4 overexpression and transposase co-expression

   PMID:18071335

   Open questions at the time

   • Mechanism of HMGXB4 activation of the SB 5′-UTR (direct DNA binding vs. cofactor recruitment) unresolved
   • Relevance to endogenous transposable element regulation in the human genome not addressed
3. 2010 High

   The mechanism by which HMGXB4 represses smooth muscle differentiation was defined: it directly binds myocardin via N-terminal domains, disrupting the SRF–myocardin complex and preventing activation of smooth muscle gene promoters.

   Evidence GST pulldown with domain mapping, overexpression and knockdown in smooth muscle cells, ChIP showing loss of SRF-myocardin occupancy, reporter assays

   PMID:20511232

   Open questions at the time

   • Whether HMGXB4 regulates myocardin-dependent genes in vivo (e.g., in vascular injury) was untested at this stage
   • Structural basis of the HMGXB4–myocardin interaction unknown
4. 2021 High

   HMGXB4 was established as a direct transcriptional activator of proinflammatory genes (Nos2 in macrophages, Icam1 in endothelial cells), and its genetic deletion in mice conferred protection against sepsis and LPS-induced lung injury, defining its in vivo role in innate immune inflammation.

   Evidence Hmgxb4 knockout mice subjected to LPS and CLP models, ChIP-seq showing promoter binding, transcriptome profiling, pharmacological NOS2 inhibition rescue, monocyte adhesion assay

   PMID:33563757

   Open questions at the time

   • Upstream signals activating HMGXB4 in inflammatory contexts (beyond LPS) not defined
   • Whether HMGXB4 binds DNA directly at Nos2/Icam1 promoters via its HMG box or requires cofactors is not resolved
5. 2023 Medium

   The upstream regulation of HMGXB4 itself was mapped: ERK2/ELK1 activates its transcription, KRAB-ZNF/TRIM28 represses it epigenetically, and SUMOylation controls its transcriptional output by directing nucleolar compartmentalization and altering protein interaction affinities.

   Evidence Promoter-chromatin looping analysis, transcription factor binding assays, SUMOylation assays, nucleolar localization imaging, protein interaction studies

   PMID:37108449

   Open questions at the time

   • Identity of specific SUMO sites and SUMO E3 ligases responsible not defined
   • Functional consequences of nucleolar sequestration on specific target gene sets not tested genome-wide
   • Whether ERK2/ELK1 regulation of HMGXB4 operates in inflammatory as well as transposon contexts not addressed
6. 2024 Medium

   In vivo reporter analysis confirmed HMGXB4 as a widely expressed nuclear protein whose expression is induced by arterial injury, linking its earlier in vitro smooth muscle regulatory role to a physiological vascular response.

   Evidence Gene trap lacZ reporter mouse with β-galactosidase activity after carotid injury, subcellular fractionation

   PMID:38644513

   Open questions at the time

   • Whether injury-induced HMGXB4 promotes or restrains neointima formation in vivo not determined
   • No loss-of-function vascular injury phenotype reported

• Key unresolved questions include whether HMGXB4 binds DNA directly through its HMG box at inflammatory and smooth muscle gene promoters, the structural basis of its interactions with myocardin and NLK, the physiological consequence of its loss in vascular injury, and whether its roles in Wnt signaling, inflammation, and transposon regulation reflect a unified chromatin-remodeling mechanism.
• No crystal or cryo-EM structure of HMGXB4 or its complexes
• DNA-binding specificity of the HMG box domain not characterized by SELEX or structural methods
• No human genetic disease association established in the provided literature